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WHAT THIS PAPER ADDS
 Historically, outcome after repair of symptomatic AAAs has been consistently worse than non-ruptured elective AAA patients when
treated with conventional open surgical techniques. The inability to take the necessary time for an adequate preoperative work-up
might have been one of the reasons for this difference. Recent series of symptomatic patients treated with endovascular aneurysm
repair have shown much better outcomes. However, numbers of endovascular-treated symptomatic AAAs in these series were
small. This study compared 185 symptomatic AAAwith 1015 asymptomatic AAA, all treated with EVAR, and represents a combined
contemporary experience of 77 sites in 30 countries.a r t i c l e i n f o
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Aim: This study aimed to compare the differences in perioperative outcome after endovascular repair of
symptomatic abdominal aneurysms (S-AAAs) and elective non-symptomatic AAAs (E-AAAs). Data from
the ENGAGE Registry were used for the analysis.
Methods: Between March 2009 and December 2010, 1200 AAA patients were enrolled from 79 sites in 30
countries and treated with an Endurant Stent Graft. S-AAAs deﬁned as AAAs accompanied by abdominal
or back pain, without rupture, were present in 185 (15.4%) patients and E-AAAs in 1015 (84.6%) patients.
Multivariate logistic regression was used to compare results.
Results: At baseline, E-AAA patients had larger aneurysms on average (P ¼ 0.006) and scored higher ASA
classiﬁcation more often (P ¼ 0.001). Further analyses were corrected for baseline differences. Operation
time and technical success were comparable, and S-AAAs were admitted to the Intensive Care Unit (ICU)
as often as E-AAAs (35.7% vs. 33.4%, P ¼ 0.479). Post-operative hospitalisation was similar (4.83  5.29 in
E-AAAs and 4.37  3.49 in S-AAAs, P ¼ 0.360). No differences in the occurrence of major adverse events,
including mortality, within the 30-day post-implantation were seen between S-AAA and E-AAA patients,
respectively, 3.2% and 4.2% (P ¼ 0.572).
Conclusion:With contemporarydevices and technicalproﬁciency, there isnodifference inoutcomebetween
symptomatic AAA and elective non-symptomatic AAA patients if treated with endovascular techniques.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The introduction of endovascular aneurysm repair (EVAR) as
treatment for patients with abdominal aortic aneurysms (AAAs)
has reduced perioperative mortality and morbidity.1e4 In the last
two decades, numerous studies have been conducted to evaluatef Vascular Surgery, Catharina
Eindhoven, The Netherlands.
.
ciety for Vascular Surgery. Publishethe post-operative results of EVAR. Most of these studies distin-
guish between elective AAA (E-AAA) patients and patients with
a ruptured aneurysm (R-AAA), who present in an emergency
setting. The perioperative outcome varies with the clinical
presentation and the acuity inwhich surgical treatment is required.
In contemporary practice the mortality rate of elective EVAR is
approximately 1.4%, whereas the mortality rate in conventional
open repair is approximately 3.5%.5 Mortality in acute R-AAA repair
declined only gradually in recent decades.6,7 Several studies
observed a substantial reduction in perioperative mortality afterd by Elsevier Ltd. All rights reserved.
Table 1
Endurant stent graft instructions for use.
One of the following criteria:
- Maximal AAA diameter >5 cm
- Maximal AAA diameter >4 cm and <5 cm, with increase 0.5 cm
in past 6 months
- Maximal AAA diameter 1.5 times the diameter of the referenced aorta
AND
One of the following criteria:
- Infrarenal neck length 10 mm with non-signiﬁcant calciﬁcation,
and/or non-signiﬁcant thrombus in combination with 45 suprarenal
angulation and 60 infrarenal angulation.
- Infrarenal neck length 15 mm with non-signiﬁcant calciﬁcation
and/or non-signiﬁcant thrombus in combination with 60 suprarenal
angulation and 75 infrarenal angulation.
AND
All of the following criteria:
- Adequate iliac/femoral access
- Proximal AAA neck diameter 19 mm and 32 mm
- Distal iliac ﬁxation site diameter 8 mm and 25 mm
- Distal non-aneurysmal iliac ﬁxation length 15 mm bilaterally
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EVAR is applied in only a small fraction of R-AAA patients. A recent
Vascunet report showed a mortality rate of approximately 20% in
endovascular R-AAA repair, but EVAR was employed in only 10% of
all R-AAA repairs; the overall perioperative mortality in R-AAA
patients still averaged approximately 32%.5
In patients who undergo urgent AAA repair for the treatment of
a non-ruptured symptomatic AAA (S-AAA), prognosis is different.
S-AAA patients present with symptoms of abdominal and/or back
pain associated with aneurysmal tenderness at physical examina-
tion. As these symptoms might be a sign of impending rupture, S-
AAAs require urgent surgery. Historically, the reported outcome
after repair of S-AAA has been consistently worse than that of E-
AAA repair, with a mortality rate averaging 16%.6,13 The inability to
take the necessary time for an adequate preoperative work-up is
suggested to be one of the reasons for this difference.13 More recent
series with higher proportion of endovascular-treated S-AAAs
report results that are comparable to those for elective EVAR.8,14e17
However, these series are small and lack a concurrent group of
elective procedures. Nevertheless, the use of EVAR in this subset of
patients is promising, especially with the use of new devices with
fewer sizing constraints.
The aim of the present study was to compare the outcome of
urgent EVAR for symptomatic AAAs versus elective EVAR for
asymptomatic AAAs, within the context of contemporary, multi-
centre, real world, global, experience with a latest generation
endograft device.
Materials and Methods
Patients and database
Data from 1200 patients prospectively enrolled in the Endurant
Stent Graft Natural Selection Global Post-market Registry (ENGAGE)
were used for this analysis. The ENGAGE Registry was undertaken to
quantify the real life performance of the Endurant Stent Graft
(Medtronic Vascular, Santa Rosa, CA, USA), which is specially
designed to broaden the EVAR eligibility range. From March 2009
until November 2010, ENGAGE prospectively enrolled 1200 patients
from 79 sites in 30 countries throughout the world. All patients had
to be considered eligible candidates for EVAR treatment with the
Endurant endograft in the opinion of their ownphysician. In practice,
however, 16.8% of the enrolled AAA patients fell outside of Endur-
ant’s Instructions for use (IFU) criteriae criteria already broader than
other stent grafts. Of note, both symptomatic and asymptomatic
patients were enrolled in the ENGAGE registry, but no patients with
ruptured aneurysms or haemodynamically instable patients were
enrolled. Further methodological details of the ENGAGE Registry
have been published previously.18
Deﬁnitions and outcome
Retrospectively, patients were separated into symptomatic and
asymptomatic patients based on responses to baseline question-
naires. Data on physical examination were recorded in this ques-
tionnaire. All AAA patients with preoperative symptoms of
abdominal and/or back pain associated with aneurysm tenderness
at physical examination were considered to have S-AAA. Patients
without such symptoms of abdominal and/or back pain were
considered to have E-AAA.
Pre-existing medical comorbidities and cardiovascular risk
factors were recorded when patients were enrolled in the registry.
Tobacco use, hypertension and hyperlipidaemia were included as
cardiovascular risk factors. Patients’ medical records were evalu-
ated for a history of diabetesmellitus, cancer (not speciﬁed), cardiacdiseases (myocardial infarction, arrhythmia, angina pectoris,
congestive heart failure, coronary artery disease, cardiac revascu-
larisation and valvular heart disease), chronic pulmonary diseases
(not speciﬁed), renal insufﬁciency, carotid artery disease, cerebro-
vascular diseases (transient ischaemic attack and cerebral vascular
accident), peripheral vascular diseases and gastrointestinal
complications. In addition, the patients’ preoperative health status
was classiﬁed according to the American Society of Anaesthesiol-
ogists Classiﬁcation of Health (ASA classs IeIV).19
Prior to the EVAR procedure, computed tomography angiog-
raphy (CTA) imaging of the abdomen and pelvis was undertaken to
determine baseline aortic and aneurysmal dimensions. Patients
were classiﬁed by primary indication for aneurysm repair accord-
ing to the Society of Vascular Surgery international AAA guide-
lines.20,21 Indications for repair included a maximum AAA diameter
>5 cm, or 4e5 cm with an increase of 0.5 cm in last 6 months, or
1.5 times normal infrarenal aorta diameter. Patients were
considered to fall outside of the device IFU when the proximal neck
diameter or length, infrarenal or suprarenal angulation, or distal
iliac ﬁxation diameter or length did not fall within the speciﬁca-
tions of Endurant’s IFU (Table 1).
The primary outcome of the analysis was perioperative
mortality, deﬁned as mortality from any cause occurring within 30
days of surgery. Secondary outcome measures for this analysis
included procedural data, major perioperative adverse events
(MAEs), technical success and clinical success. Procedural data
included duration of the implant procedure, total volume of
contrast used, post-operative hospitalisation and admission rate to
the Intensive Care Unit (ICU). Technical success was deﬁned as
successful delivery and deployment of the Endurant endograft,
without unintentional coverage of renal arteries, internal iliac
arteries or visceral branches, followed by successful removal of the
delivery system. Initial clinical success was deﬁned as technical
success without intra-operative death or presence of a type I/III
endoleak at the end of the procedure. MAEs included all-cause
mortality, bowel ischaemia, myocardial infarction, paraplegia,
renal failure, respiratory failure, stroke and procedural blood loss
1000 ml. Follow-up data 30 days after implantation were
completed for all patients.Data collection and statistical analysis
Data collected on each patient were recorded on a web-based
electronic case report form (Viracity Clinical Asset Manage-
ment, MERGE Healthcare, Chicago, IL, USA). Data were entered by,
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research analysts from Medtronic Bakken Research Centre BV
(Maastricht, The Netherlands) cross-checked over 40% of patients’
source documentation against the entered data during monitoring
visits. Data collection and analysis was approved by each site’s
Institutional Review Board, and informed consent for authorisation
of data release was obtained in all patients.
Statistical analysis was performed using SAS version 9.0 software
for Windows (SAS Institute Inc., Cary, NC, USA). To analyse outcome
differences in E-AAA versus S-AAA patients, a multivariate logistic
regressionmodelwas used for categorical response variables. To adjust
for demographic and baseline risk factors, age, gender and ASA clas-
siﬁcation were included as covariates in the model. For continuous
response variables, a generalised linear model or covariance analysis
model was applied and rank transformed data were also examined as
a sensitivity analysis. Missing values were excluded from analysis.
Categorical variables are presented as frequency with percentages.
Continuous variables are presented as mean  standard deviation
(SD). Values of P < 0.05 were considered statistically signiﬁcant.
Results
Patient characteristics
Among the 1200 consecutive patients enrolled in the ENGAGE
registry, 1015 (84.6%) were asymptomatic and 185 (15.4%) wereTable 2
Patient demographics & risk factors (ITT analysis).
Variable Asymptomatic AAAa
N ¼ 1015 Mean  SD or %
Age (years) 73.6  7.9
Gender
Male 90.4% (918/1015)
Female 9.6% (97/1015)
ASAb classiﬁcation
Class I 4.7% (48/1012)
Class II 40.4% (409/1012)
Class III 42.9% (434/1012)
Class IV 12.0% (121/1012)
Maximum AAAa diameter (mm) 60.0  11.1
Indication by AAAa diameter
1.5 normal infrarenal aorta 2.4% (24/1015)
4e5 cm (0.5 cm increase in 6 months) 5.8% (59/1015)
>5 cm 89.6% (909/1015)
Other 2.3% (23/1015)
Circumferential aortic mural thrombus
at the proximal neck (%)
10.41  17.4
Risk factors
Tobacco use 48.6% (481/990)
Hypertension 75% (756/1002)
Hyperlipidaemia 61.9% (594/960)
Diabetes 20.0% (200/999)
Cancer 20.8% (207/997)
Cardiac disease
Myocardial infarction (MI) 27.3% (266/973)
Arrhythmia 16.8% (167/992)
Angina 15.9% (157/990)
Congestive heart failure (CHF) 5.7% (56/987)
Coronary artery disease (CAD) 35.4% (348/982)
Cardiac revascularization 28.4% (285/1002)
Valvular heart disease 6.0% (60/992)
Pulmonary disease 24.4% (243/996)
Renal insufﬁciency 15.8% (159/1006)
Carotid artery disease 11.9% (100/841)
Cerebrovascular disease
Transient ischemic attack (TIA) 5.4% (54/1002)
Cerebral vascular accident (CVA) 5.5% (55/1008)
Peripheral vascular disease 18.0% (180/998)
Gastrointestinal complications 20.4% (207/1014)
a Abdominal aortic aneurysm.
b American Society of Anesthesiologists.symptomatic. No patients with ruptured aneurysm were enrolled
in this study.
Demographic data and baseline risk factors are presented in
Table 2. On average, S-AAA patients were younger than E-AAA
patients, with a mean age of 71.7 8.9 years versus 73.6 7.9 years
(P ¼ 0.012). Patients were predominantly men and the distribution
of sexes was comparable between the groups. Symptomatic
presentation was less likely to occur in patients with a history of
carotid artery disease compared with E-AAA patients (P ¼ 0.039),
but patients did not differ signiﬁcantly by smoking status or other
pre-existing comorbid diseases. Nevertheless, E-AAA patients were
signiﬁcantly more likely to be in ASA classes III and IV than were
S-AAA patients. The distribution of ASA classes IeIV in E-AAA
versus S-AAA patients was 4.7%, 40.4%, 42.9%, and 12.0% versus
6.5%, 51.9%, 35.7%, and 5.9%, respectively (P< 0.001). Only ASA class
remained a signiﬁcant baseline covariate in multivariate analysis;
therefore, further analyses on the outcome variables were cor-
rected for ASA classiﬁcations.
Compared with E-AAA patients, S-AAA patients had more often
an AAA diameter of 1.5 times the normal infrarenal aorta diam-
eter or AAA diameter of 4e5 cmwith a0.5 cm increase within the
last 6 months, and less often an AAA diameter of>5 cm (5.9%, 10.3%
and 81.6%, and 2.4%, 5.8% and 89.6%, respectively, P ¼ 0.002). Mean
maximum AAA diameter was, however, larger in S-AAA thanwas in
E-AAA patients, 62.7  14.3 mm versus 60.0  11.1 mm (P ¼ 0.004).
The proportion of patients treated outside IFU was comparable in(m/n)
Symptomatic AAAa
N ¼ 185 Mean  SD or %(m/n)
P-value
71  8.9 .012
n.s.
85.9% (159/185)
14.1% (26/185)
<.001
6.5% (12/185)
51.9% (96/185)
35.7% (66/185)
5.9% (11/185)
62.7  14.3 .004
.002
5.9% (11/185)
10.3% (19/185)
81.6% (151/185)
2.2% (4/185)
10.09  18.1 n.s.
51.4% (92/179) n.s.
77.9% (141/181) n.s.
63.1% (106/168) n.s.
14.1% (26/184) n.s.
16.9% (31/183) n.s.
26.0% (46/177) n.s.
14.4% (26/180) n.s.
16.5% (30/182) n.s.
7.2% (13/180) n.s.
30.5% (53/174) n.s.
21.7% (39/180) n.s.
7.1% (13/182) n.s.
31.1% (57/183) n.s.
14.2% (26/183) n.s.
6.3% (10/159) .039
3.8% (7/185) n.s.
4.9% (9/185) n.s.
22.8% (42/184) n.s.
20.0% (37/185) n.s.
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that fell outside of the IFU (Table 3).
Procedure details
Initial procedural data and evaluation are detailed in Table 4.
The endovascular procedure was terminated in four patients due to
access problems caused by tortuous or stenotic iliac arteries. Two
patients required immediate conversion to open surgery: one case
for unintentional coverage of both renal arteries and one case in
which the surgeon was unable to remove the delivery device when
a suprarenal strut became entrapped in the delivery system. In ﬁve
other cases, the internal iliac artery was unintentionally covered.
All seven procedural problems occurred in E-AAA patients, result-
ing in a technical success rate of 98.9% in this group of patients,
compared with 100% in the S-AAA group, a difference that did not
attain statistical signiﬁcance (adjusted P ¼ 0.163). Initial clinical
success rate was 97.3% in E-AAA patients, with 16 cases of type I
and/or III endoleaks at the end of the initial procedure as well as the
11 technical failures. Initial clinical success rate was 99.5% in the
S-AAA patients, with one type I endoleak, a rate that did not differ
from that of E-AAA group (adjusted P ¼ 0.085). The mean duration
of the implant procedure and mean volume of contrast used were
similar between E-AAA and S-AAA repairs. S-AAA patients under-
went the procedure with local or regional anaesthesia more often
than E-AAA patients (adjusted P ¼ 0.003). No differences were
noted in ICU admission rate and days of post-operative hospital-
isation between both groups of patients after adjustment for
ASA class.Table 3
Patients implanted outside IFUa (PP-analysis).
Variable Asymptomati
N ¼ 1009
Total implanted outside of IFUa guidance 15.8% (159/10
Non-primary indications 2.3% (23/100
Proximal neck diameter <19 mm or >32 mm 3.9% (39/100
Proximal neck length <10 mm 2.2% (22/100
Proximal neck length 10 mm and <15 mmc 1.8% (18/100
Angulation suprarenal >60 or infrarenal >75 5.0% (50/100
Distal iliac ﬁxation site diameter <8 mm 1.5% (15/100
Distal iliac ﬁxation site diameter >25 mm 1.1% (11/100
a Instructions for use.
b Abdominal aortic aneurysm.
c In combination with suprarenal angle >45 or infrarenal angle >60 .
Table 4
Initial procedural data and evaluation (ITT analysis).
Variable Asymptomatic AAAa
N ¼ 1015
Duration of implant procedure (mins) 100.9  45.3
Type of anaesthesia
General 64.5% (654/1014)
Spinal/Epidural 25.7% (261/1014)
Local 9.8% (99/1014)
Volume of contrast (mL) 130.2  71.0
Post-operative stay (days) 4.83  5.29
Time in ICUc (hours) 10.0  45.9
Admission to ICUc 33.4% (339/1015)
Evaluation
Intra-operative mortality 0.0% (0/1015)
Technical success 98.9% (1004/1015)
Clinical success 97.3% (988/1015)
a Abdominal aortic aneurysm.
b P-value adjusted for baseline ASA classiﬁcation.
c Intensive Care Unit.Mortality and morbidity
There were no intra-operative deaths in the 1200 patients.
Within 30 days after implant, 15 E-AAA patients died versus 1 S-
AAA patient, resulting in perioperative mortality rates of 1.5% and
0.5% (adjusted P ¼ 0.316) in E-AAA and S-AAA patients, respec-
tively. The occurrence of one or more MAEs, including mortality,
within 30 days after the initial procedure was similar in the groups;
30-day MAE’s rate was 4.2% in E-AAA patients and 3.2% in S-AAA
patients (adjusted P ¼ 0.572). Finally, there were no signiﬁcant
differences in the relative proportions of different types of MAEs in
the two groups (Table 5).
Discussion
Whenever an AAA patient presents with symptoms that suggest
that a rupture is imminent, surgeons are confronted with a difﬁcult
challenge in clinical practice. They have to make a choice whether
to urgently operate a patient, who may not be optimised for major
surgery, or to postpone surgery until regular preoperative work-up
is completed. Historically, urgent S-AAA repair has had a worse
perioperative outcome than elective E-AAA repair.13,22e27 Post-
poning surgery, however, includes a risk of interval rupture, which
is associated with an even higher mortality rate.5,6 After EVAR has
proved itself in elective patients; this technique is nowadays also
more often applied in urgent cases.8,12,15,28 This studymight resolve
a part of the practical dilemma, as it shows that there no longer is
a difference in outcome between S-AAA patients and E-AAA
patients after endovascular repair.c AAAb Symptomatic AAAb
N ¼ 185
P-value
09) 20.0% (37/185) n.s.
9) 2.2% (4/185) n.s.
4) 6.0% (11/183) n.s.
0) 1.7% (3/180) n.s.
0) 2.2% (4/180) n.s.
0) 6.7% (912/180) n.s.
9) 2.2% (4/185) n.s.
9) 0.0% (0/185) n.s.
Symptomatic AAAa
N ¼ 185
P-value Adjusted
P-valueb
95.0  42.5 .097 .323
51.4% (95/185) .001 .003
34.6% (64/185)
14.1% (26/185)
132.2  66.3 .738 .858
4.37  3.49 .253 .360
10.6  27.8 .861 .872
35.7% (66/185) .547 .479
0.0% (0/185) e e
100.0% (185/185) .155 .163
99.5% (184/185) .079 .085
Table 5
Major adverse events within 30 days (ITT analysis).
Variable Asymptomatic
AAAa N ¼ 1015
Symptomatic
AAAa N ¼ 185
P-value Adjusted
P-valueb
One or more (MAEs) 4.2% (43/1015) 3.2% (6/185) .530 .572
All-cause Mortality 1.5% (15/1015) 0.5% (1/185) .307 .316
Bowel ischemia 0.2% (2/1015) 0.5% (1/185) .390 .378
Myocardial infarction 1.2% (12/1015) 1.1% (2/185) .906 .975
Paraplegia 0.0% (0/1015) 0.0% (0/185) e e
Renal failure 0.3% (3/1015) 0.5% (1/185) .068 .066
Respiratory failure 0.0% (0/1015) 0.0% (0/185) .595 .484
Stroke 0.1% (1/1015) 0.5% (1/185) e e
Procedural blood loss 1000 mL 1.8% (18/1015) 0.0% (0/185) .175 .191
a Abdominal aortic aneurysm.
b P-value adjusted for baseline ASA classiﬁcation.
R.A. Stokmans et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 667e673 671Previous studies that have compared symptomatic aneurysms
with elective cases in open surgical repair found 30-day mortality
rates in S-AAAs ranging from 9.5% to 26.0%13,22e27 versus approx-
imately 5% in E-AAAs.1e4 Recent data showed 30-day mortality
rates within the range of 0e5% in S-AAA when treated with
EVAR.8,14,16,17 However, these studies describe only a low number of
endovascular S-AAA repairs. In all, but one study, results arrived
from single centre experience andwere gathered over a long period
of time. Often, no direct comparison to E-AAA patients was
performed.8,16,17
The current study represents worldwide and contemporary
experiences of 79 sites in 30 countries. It represents the largest
series of endovascular S-AAA repairs ever reported. Results
showed no differences in 30-day mortality and morbidity rates
after EVAR between S-AAA and E-AAA patients. It shows that
perioperative mortality risk has reduced remarkably with current
endovascular S-AAA repair when compared to mortality risks in
the era of open surgical repair. However, this conclusion must be
taken with caution since the effects of selection bias in this study
are unknown. All patients underwent optimal preoperative
imaging and were considered to have adequate anatomy for EVAR
treatment, which might be different for the S-AAA patients
included in series of open surgical repair. Furthermore, the level of
external validity might be argued upon. Since ENGAGE describes
only the results of the Endurant Stent Graft, the results of this
study might not necessarily be generalised to all endografts
available on the market.
This study showed that the type of AAA had no inﬂuence on
progress of EVAR procedure. Operation time and the amount of
contrast used were not different in S-AAA repair compared with E-
AAA repair, and afterward S-AAA patients did not require more
referral to the ICU or longer hospitalisation than the E-AAA
patients. The technical success rate in both AAA subsets was similar,
with no failure at all in S-AAA repair. Although not statistically
signiﬁcant, it is remarkable that only in the E-AAA group some
patients required conversion to open surgery because of inacces-
sible iliac arteries or intra-operative problems. Except from a low
overall incidence rate of conversions in the ENGAGE cohort, no
other possible explanations can be given for this.
A proportion of 15.4% S-AAA from a cohort of unruptured AAA
repairs is within the range of 5e23% noted in previous
reports.12e15,23,25,26 There is a lack of universally adapted criteria
for a deﬁnition of symptomatic AAA patients. Therefore, in this
study the deﬁnition described by Peppelenbosch et al.12 was used,
which has been used in other studies as well.8,14,15 The ENGAGE
database was not speciﬁcally designed for this retrospective
analysis. Unfortunately, it does not routinely record time from
EVAR indication to initial procedure. Therefore, it remains unclear
if all S-AAAs were treated in a semi-acute setting and if E-AAAs
were not.Conclusion
Endovascular AAA repair is a dynamic endeavor; new devices
and perioperative care have improved and operators have become
more proﬁcient resulting in less operative burden in patients. The
ENGAGE data indicate that with contemporary devices and tech-
nical proﬁciency, there is no difference in outcome between
symptomatic AAA patients and elective non-symptomatic AAA
patients if treated with endovascular techniques.
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